WallStSmart

Impact BioMedical, Inc. (IBO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 2020% more annual revenue ($742,000 vs $35,000). IBO leads profitability with a 2260.0% profit margin vs 0.0%. IBO earns a higher WallStSmart Score of 32/100 (F).

IBO

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 6.7Quality: 3.8
Piotroski: 4/9Altman Z: -1.58

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IBO2 strengths · Avg: 10.0/10
P/E RatioValuation
0.6x10/10

Attractively priced relative to earnings

Profit MarginProfitability
2260.0%10/10

Keeps 2260 of every $100 in revenue as profit

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

IBO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$52.83M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-112.2%2/10

ROE of -112.2% — below average capital efficiency

Revenue GrowthGrowth
-57.1%2/10

Revenue declined 57.1%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : IBO

The strongest argument for IBO centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 2260.0% and operating margin at -23400.0%.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : IBO

The primary concerns for IBO are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

IBO profiles as a declining stock while RVMD is a value play — different risk/reward profiles.

IBO is growing revenue faster at -57.1% — sustainability is the question.

IBO generates stronger free cash flow (470,000), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IBO scores higher overall (32/100 vs 24/100), backed by strong 2260.0% margins. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Impact BioMedical, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Utilizing advanced research methodologies, the firm aims to improve patient outcomes and overall quality of life. With a robust intellectual property portfolio and an emphasis on scientific rigor, Impact BioMedical is well-positioned for growth in the evolving healthcare market. Its extensive product pipeline and strategic collaborations offer attractive investment opportunities for institutional investors interested in the accelerating biopharmaceutical sector.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?